Equillium reports lower-than-expected Q4 net loss
Overview
US biotechnology firm's fiscal Q4 net loss narrowed, beating analyst expectations
Outlook
Equillium plans to initiate Phase 1 EQ504 study in mid-2026, with data in late 2026
Company expects cash and equivalents, inclusive of the March 2026 financing, to fund operations into 2029
Result Drivers
R&D SPENDING DECLINE - Co said lower R&D expenses were primarily due to the wind down of clinical studies in 2025
Company press release: ID:nGNXpSrM4
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 EPS | Beat | -$0.04 | -$0.06 (4 Analysts) |
Q4 Net Income | Beat | -$3.78 mln | -$5.06 mln (4 Analysts) |
Q4 Operating Income | Beat | -$3.96 mln | -$4.73 mln (4 Analysts) |
Q4 Operating Expenses |
| $3.96 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Equillium Inc is $4.50, about 130.8% above its March 24 closing price of $1.95
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
